21
Views
34
CrossRef citations to date
0
Altmetric
Research

Patent Update Central & Peripheral Nervous Systems: Glycine-site NMDA receptor antagonists: an update

Pages 1069-1079 | Published online: 29 Feb 2008

References

  • LEESON PD, IVERSEN LL: The glycine site on the NMDA receptor: structure-activity relationships and therapeu-tic potential. J. Med. Chem. (1994) 37:4053–4067.
  • WARNER DS, MARTIN H, LUDWIG P et al.: In vivo models of cerebral ischemia: effects of parenterally adminis-tered NMDA receptor glycine antagonists. J. Cereb. Blood Flow Metab. (1995) 15:188–196.
  • GILL R, HARGREAVES RJ, KEMP JA: The neuroprotectiveeffect of the glycine site antagonist 3R-(+)-cis-4-methyl-HA966 (L-68'7,414) in a rat model of focal ischemia. Cereb. Blood Flow Metab. (1995) 15:197–204.
  • TRICKLEBANK MD, BRISTOW LJ, HUTSON PH et al.: The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex. Br. J. Pharmacol. (1994) 113:729–736.
  • KULAGOWSKI JJ, LEESON PD: Glycine-site NMDA receptor antagonists. Exp. Opin. Ther. Patents (1995) 5:1061–1075.
  • DORMAN PJ, COUNSELL CE, SANDERCOCK PAG: Recently developed neuroprotective therapies for acute stroke. A qualitative systematic review of clinical trials. CNS Drugs (1996) 5:457–474.
  • RATri E, CORSI M, CARIGNAN' C et al.: Pharmacological characterisation of the novel glycine antagonist GV150526A: in vitro studies. Fur. J. Neurology (1995) 2\(Suppl. 2):57.
  • DI FABIO R, CUGOLA A, DONATI D et al.: Novel substi-tuted indole-2-carboxylates as potent glycine antago-nists. 211th ACS Meeting. New Orleans, USA (1996). MEDI107.
  • PIETRA C, ZIVIANI L, VALERIO E, TARTER G, REGGIANI A: Neuroprotection by GV150526A: a comparison with reference compounds. Stroke (1996) 27:189. Abstract 130.
  • DANYSZ W, PARSONS CG, BRESINK I, QUACK G: Gluta-mate in CNS disorders. Drug News Perspect. (1995) 5:261–277.
  • Scrip (1996) 2137:11.
  • WEBER E: Studies on the side-effect profile of the glycine-site NMDA antagonist ACEA 1021 in rats and in healthy human volunteers. 25th Annual Meeting Neurosciences, Satellite Symposium on Pre- and Post-synaptic Modulation of the Glutamate Receptors. San Diego, USA (1995).
  • Pharm. Bus. News (1995) 11(256):26.
  • Analysts Meeting. CoCensys (1996).
  • BARE TM, SPARKS RB, SMITH RW et al.: PyridazIno[4,5-blquinolinediones: novel potent glycine site NMDA an-tagonists showing neuroprotectant activity in stroke models. 211th ACS Meeting. New Orleans, USA (1996). MEDI105.
  • TAKANO T, FORMATO JE, TATLISUMAK T et al.: Effects ofthe glycine antagonist ZD9 379 on experimental focal brain ischemia in rats. Stroke (1996) 27:188. Abstract 125.
  • PULLEN LM, SISSON DF, BARE TM, CHAPDELAINE MJ, STUMPO RJ: Neuroprotective glycine antagonists such as ZD9379 do not produce behavioural and elec-troencephalographic effects characteristic of other classes of N-methyl-D-aspartate antagonists. Neurology (1996) 46(2 Suppl.):A194. Abstract P02.090.
  • KEANA JFW, KHER SM, CAI SX et al.: Synthesis and structure-activity relationships of substituted 1,4-dihy-droquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors. f. Med. Chem. (1995) 38:4367–4379.
  • ZHENG H, ESPITIA SA, ILYIN V et al.: 1-Hydroxy-1,4-dihy-droquinoxaline-2,3-diones: novel antagonists at NMDA receptor glycine sites. Btoorg. Med. Chem. Lett. (1996) 6:439–440.
  • BRISTOW g,FLATMAN KL, HUTSON PH et al.: The atypicalneuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist L-701,324, in rodents. J. Pharm. Exp. Ther. (1996) 277:578–585.
  • ROWLEY M, LEESON P, GRIMWOOD S, MARSHALL 5: 5,6,7,8-Tetrahydroquinolones as antagonists at the gly-cine site of the NMDA receptor. BiooT. Med. Chem. Lett. (1995) 5:2089–2092.
  • YIT S-Y, EHRGOTT FJ, GAO J, MEANWELL NA: 3-Hydroxy-uinolin-2-ones: inhibitors of [311]-glycine binding to the site associated with the NMDA receptor. Bioorg. Med. Chem. Lett. (1996) 6:499–504.
  • CHAPDELAINE MJ, MCLAREN CD, WILDONGER RA et al.:Glycine site antagonists of the NMDA receptor complex: 3-hydroxy-2,5-dioxo-1H-benz[b]azepines. 211th ACS Meeting. New Orleans, USA (1996). MEDI109.
  • MCLAREN CD, CHAPDELAINE MJ, PAYNE-GALLIMORE PA,WILDONGER RA, PULLAN LM: 3-Benz[b]azepinyl acry-lates as precursors to a variety of potential glycine antagonists. 211th ACS Meeting. New Orleans, USA (1996). MEDI044.
  • JACKSON PF, DAVENPORT TW, GARCIA L et al.: Synthesisand biological activity of a series of 4-aryl substituted benz[b]azepines: antagonists at the strychnine-insensi-tive glycine site. Bioorg. Med. Chem. Lett. (1995) 5:3097–3100.
  • PAYNE-GALLIMORE PA, CHAPDELAINE MJ, HARRIS GG etal.: 3-Amino-2,5-dihydro-2,5-dioxo-1H-benz[blazepines isosteres and prodrugs for 2,5-dihydro-3-hydroxy-2,5-dioxo-1H- benziblazepines. 211th ACS Meeting. New Or-leans, USA (1996). MEDI047.
  • GUZIKOWSKI AP, HAWKINSON J, WEBER E, KEANA JEW:6,7,8,9-Tetrahydro-3-hydroxy-1H-1-benzepine-2,5-d-Jones via a Diels-Akler reaction: antagonists with a non-planar hydrophobic region for NMDA receptor glycine sites. Bioorg. Med. Chem. Lett. (1995) 5:2747–2748.
  • BARE TM, SMITH RW, DRAPER CW et al.: Syntheses and structure activity relationships of 1-hydroxy-3,4,3,10-tetrahydropyridazino[4,5-b]quinoline-4,10-diones: an-tagonists at the glycine site of the NMDA receptor. 211th ACS Meeting. New Orleans, USA (1996). MEDI038.
  • EMPFIELD JR, FORST J, HERZOG KJ et al.: 7-Chloro-4-hy-droxy-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones: synthetic studies and glydne antagonism of N-2-benzyl and related analogs. 211th ACS Meeting. New Orleans, USA (1996). MEDI041.
  • EMPFTELD JR, FORST J, HERZOG KJ et al.: 2-Alky1-7-chloro-4-hydroxy-1,2,5,10-tetrahydropyridazino[4,5-b]quinol ine-1,10-diortes: glycine site antagonism of the NMDA receptor and in vivo functional activity. 211th ACS Meet-ing. New Orleans, USA (1996). MEDI042.
  • BARE TM, SPARKS RB, SCHREFFLER-SMITH CN et al.: 2-Arylpyridazinoquinolinediones: novel glycine site NMDA antagonists with potent in vitro and in vivo properties. 211th ACS Meeting. New Orleans, USA (1996). MEDI039.
  • DAVENPORT TW, BARE TM, GARCIA-DAVENPORT LE eta/.:Synthesis and activity of a series of pyriti27inoquinoli-nes, pyridazinobenzothiazines, and pyridazinoindoles; antagonists at the strychnine-insensitive glycine recep-tor site. 211th ACS Meeting. New Orleans, USA (1996). MEDI043.
  • CURTIS NR, KULAGOWSKI JJ, LEESON PD et al.: Synthesisand SAR of diiodotyrosine-derived glycine-site N-methyl-D-aspartate receptor ligands. Bioorg. Med. Chem. Lett. (1996) 6:1145–1150.
  • MAWER IM, KULAGOWSKI JJ, LEESON PD, GRIM WOOD S, MARSHALL GR: Tetramic adds as novel glycine site antagonists. Bioorg. Med. Chem. Lett. (1995) 5:2643–2648.
  • BOIREAU A, MALGOURIS C, BURGEVIN M-C et al.: Neuro-protective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro. Ear. J. Pharmacol. (1996) 300:237–246.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.